Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.
Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.
Theralase Technologies (OTCQB: TLTFF) has announced significant preclinical results for its antiviral candidate Ruvidar in treating Herpes Simplex Virus Type 1 (HSV-1). The peer-reviewed research demonstrates that Ruvidar is more effective than current gold standard treatments Acyclovir and Metformin, even without light activation.
Key findings show that Ruvidar effectively suppresses viral replication in infected cells and prevents infection spread to adjacent cells, while current treatments showed minimal effect post-infection. Notably, Ruvidar proved effective against Acyclovir-resistant HSV-1 mutants. The company plans to commence a Phase I/II adaptive clinical study in 2026 to evaluate Ruvidar's safety and efficacy in treating cold sore lesions.
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, has announced plans to extend its warrant expiration date. The company aims to extend 1,840,000 share purchase warrants from September 7th, 2025 to September 7th, 2028.
These warrants, originally issued on September 7th, 2023 through a private placement, are exercisable at CAN $0.35 per share. The extension is pending final approval from the TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company, has released its Q2 2025 financial results showing mixed performance. The company reported a 12% revenue increase to $310,933 and a 47% gross margin improvement to $131,967 for the six-month period ended June 30, 2025.
The company completed three private placements raising total gross proceeds of approximately $1.66 million. In its Study II clinical trial, 86 patients (96% of target) have been treated, with 61.4% achieving Complete Response and 70% achieving Total Response. At the 450-day assessment, 39.5% of patients maintained Complete Response, demonstrating treatment durability.
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics, has completed a non-brokered private placement. The company raised CAD $672,627 by issuing 3,363,134 units at CAD $0.20 per unit.
Each unit comprises one common share and one warrant, with warrants exercisable at CAD $0.30 for 5 years. The proceeds will support the ongoing Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, Rutherrin® development, and working capital needs. Notably, 130,000 units were issued to company insiders, representing CAD $26,000 of the total raise.
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, has announced plans to extend the expiry date of 4.8 million share purchase warrants. The warrants, originally issued on June 30th, 2023, will be extended from June 30th, 2025, to June 30th, 2028.
The warrants remain exercisable at CAN $0.35 per share, with all other terms and conditions unchanged. This extension is pending final acceptance from the TSX Venture Exchange.
Theralase Technologies (TLTFF) announced it will present new preclinical research on radiation-activated Rutherrin® at the ASTRO 2025 67th Annual Meeting in San Francisco. The study evaluates Rutherrin®, a ruthenium-based drug formulated with human transferrin, against radiation alone in treating cancer.
The research explores Rutherrin's dual cancer-fighting mechanism: immediate cytotoxicity through Reactive Oxygen Species generation and sustained immune response through Immunogenic Cell Death. Key aspects to be presented include tumor targeting, blood-brain barrier penetration, survival rates, and resistance inhibition.
The company plans to complete GLP toxicology studies in 2025 and aims to launch clinical studies in early 2026 targeting multiple cancers including GBM, lung, pancreatic, lymphoma, and colorectal cancers.